Form 990 for tax year 2023

Totals

Total revenue

$5,010,088

Total expenses

$5,075,041

Contributions and grants received

$4,516,155

Grants paid

$2,820,170

Program service revenue

$0

Investment income

$161,711

Other revenue

$332,222

Total assets, end of year

$7,031,609

Total liabilities, end of year

$930,873

Net assets or fund balances, end of year

$6,100,736

Program services expenses (Part IX)

$4,494,421

Management and general expenses

$264,970

Fundraising expenses

$315,650

Program service expenses (Part III)

$4,494,421

Program services were 88.6% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2023

• THE NATIONAL PEDIATRIC CANCER FOUNDATION FUNDS PEDIATRIC CANCER RESEARCH WITH THE GOAL OF LEADING TO THE TREATMENT AND ELIMINATION OF PEDIATRIC CANCER WORLDWIDE.WE ACCOMPLISH OUR MISSION THROUGH OUR RESEARCH INITIATIVE, THE SUNSHINE PROJECT, AN INNOVATIVE COLLABORATION OF 30 HOSPITALS NATIONWIDE. THIS COLLABORATIVE RESEARCH MODEL IS UNIQUE AND EFFECTIVE IN ACCELERATING THE DEVELOPMENT OF NEW TREATMENTS AGAINST CHILDHOOD CANCER.SEE SCHEDULE O FOR FURTHER PROGRAM SERVICE ACCOMPLISHMENTS.IN DEVELOPING THIS COLLABORATION, THE FOUNDATION HAS BROUGHT TOGETHER SOME OF THE COUNTRY'S LEADING INVESTIGATORS AND INSTITUTIONS TO DRIVE THE PROCESS OF FINDING A CURE. INVESTIGATORS ARE PERFORMING THREE VITAL PHASES OF RESEARCH SIMULTANEOUSLY: BASIC SCIENCE, TRANSLATIONAL RESEARCH AND CLINICAL TRIALS. THESE MAJOR RESEARCH COMPONENTS NOT ONLY ALLOW DOCTORS TO IDENTIFY NEW AGENTS IN FIGHTING CANCER, BUT ALSO HELP RESEARCHERS TO UNDERSTAND THE CANCER CELLS RESPONSE TO THE DRUG. THE NATIONAL PEDIATRIC CANCER FOUNDATION IS MAKING GREAT STRIDES IN ITS MISSION TO FIND A CURE FOR CHILDHOOD CANCER.CURRENT INITIATIVES OF THE SUNSHINE PROJECT ARE AS FOLLOWS:SARCOMA TRIALS (OSTEOSARCOMA, RHABDOMYOSARCOMA, EWING SARCOMA, NON-RHABDOMYOSARCOMA)1. PHASE II STUDY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE FOR TREATMENT OF RECURRENT/REFRACTORY SARCOMA IN TEENAGERS AND YOUNG ADULTS - THIS TRIAL WILL LOOK AT THIS COMBINATION OF NAB-PACLITAXEL AND GEMCITABINE IN ITS ABILITY TO PREVENT THE FORMATION OR GROWTH OF TUMORS IN TEENAGERS AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA, EWING SARCOMA, RHABDOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMA. THE TRIAL WILL ALSO LOOK AT THE LENGTH OF TIME DURING AND AFTER TREATMENT THAT THE DISEASE DOES NOT GET WORSE, AND DETERMINE IF NAB-PACLITAXEL COMBINED WITH GEMCITABINE IS SAFE AND TOLERABLE.2. A PHASE IB/II STUDY TO EVALUATE THE SAFETY, FEASIBILITY AND EFFICACY OF NIVOLUMAB OR NIVOLUMAB IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RECURRENT, RESECTABLE OSTEOSARCOMA - THIS WILL BE THE FIRST TIME BOTH DRUGS, NIVOLUMAB AND AZACITIDINE ARE BEING USED IN COMBINATION TO TREAT OSTEOSARCOMA. HIS TRIAL WILL DETERMINE IF THE COMBINATION OF AZACITIDINE AND NIVOLUMAB CAN IMPROVE EVENT FREE SURVIVAL OVER THE 20% HISTORICAL CONTROL USED FOR RECURRENT OSTEOSARCOMA STUDIES IN THE CHILDREN'S ONCOLOGY GROUP.3. EVOLUTIONARY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA - METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA (RMS) HAVE A POOR OUTCOME WHICH IS WORSENED WITH ADDITIONAL RISK FACTORS COMMONLY CALLED THE OBERLIN CRITERIA. PATIENTS THAT MEET ALL 4 OBERLIN CRITERIA HAVE AN EVENT FREE SURVIVAL (EFS) OF LESS THAN 20% AT 2 YEARS. ALL THERAPEUTIC ARMS ON THIS STUDY ARE DESIGNED TO MEET THE SAME PRIMARY AIM OF IMPROVING THE 3 YEAR EVENT FREE SURVIVAL FROM 6% TO 35% FOR THESE PATIENTS. 4. ACTION TRIAL: ADOPTIVE CELLULAR THERAPY FOLLOWING DOSE-INTENSIFIED TEMOZOLOMIDE IN NEWLY-DIAGNOSED PEDIATRIC HIGH-GRADE GLIOMAS (PHASE I) - THIS IMMUNOTHERAPY TRIAL WILL EXPLORE THE SAFETY OF ADOPTIVE CELLULAR THERAPY IN PEDIATRIC PATIENTS WITH HIGH GRADE GLIOMAS (HGG) WHO HAS RECEIVED DOSE INTENSIFIED TEMOZOLOMIDE AND DENDTRIC CELL (DC) + AUTOLOGOUS LYMPHOCYTE TRANSFER (XALT) WITH AND WITHOUT AUTOLOGOUS HEMATOPOETIC STEM CELLS (HSCS). WE WILL ALSO BE EXAMINING FEASIBILITY OF ALL ENROLLED PATIENTS COMPLETING TREATMENT AND ANALYZING PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL AFTER THIS TREATMENT. 5. BLOOD BASED BIOMARKERS FOR MINIMAL RESIDUAL DISEASE DETECTION IN PEDIATRIC SARCOMAS - THE PURPOSE OF THIS STUDY IS TO SEE IF DETECTING CELL-FREE PLASMA TUMOR DNA (PTDNA) AND CIRCULATING TUMOR CELLS (CTC) CAN PREDICT RECURRENCE OF DISEASE IN PATIENTS WHO ARE IN RADIOGRAPHIC REMISSION 2-3 WEEKS AFTER TREATMENT. PLASMA TUMOR DNA (PTDNA) IS FREE FLOATING DNA FROM THE TUMOR FOUND IN THE BLOOD STREAM AND CIRCULATING TUMOR CELLS.6. A MULTI-INSTITUTION STUDY OF TGF? IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NK CELL INFUSIONS AS ADOPTIVE IMMUNOTHERAPY IN COMBINATION WITH GEMCITABINE AND DOCETAXEL IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC BONE AND SOFT TISSUE SARCOMAS: THE TINKS TRIAL - THE PURPOSE OF THIS TRIAL IS TO DETERMINE THE SAFETY OF THE ADDITION OF ADOPTIVE TRANSFER OF UNIVERSAL DONOR, TGFB IMPRINTED (TGFBI), EXPANDED NK CELLS TO GEMCITABINE/DOCETAXEL (GEM/DOX) FOR TREATMENT OF RELAPSED AND REFRACTORY SARCOMAS AND TO DETERMINE THE 6 MONTH PROGRESSION FREE SURVIVAL ACHIEVED WTIH THIS TREATMENT.7. FEASIBILITY OF GENERATING NOVEL TRANSLATIONAL AND THERAPEUTIC STRATEGIES BASED ON A MULTICENTER, PEDIATRIC AND AYA EVOLUTIONARY TUMOR BOARD (PEDSETB) - PEDIATRIC EVOLUTIONARY TUMOR BOARD (PEDSETB) IS A MULTIDISCIPLINARY FORUM TO APPROACH AN INDIVIDUAL PATIENT'S CANCER AND PROPOSE ADDITIONAL IDEAS FOR CARE. THE PEDSETB WILL GATHER TOGETHER DISCIPLINES NOT OFTEN ENGAGED IN CANCER WORK AND USE INSIGHTS FROM EVOLUTION TO OPTIMALLY MODEL, RESEARCH, AND IMPACT PEDIATRIC CANCER OUTCOMES. STRATEGIES FROM PEDSETB'S PREDECESSOR HAVE BEEN INSTRUMENTAL IN THE DESIGN OF SEVERAL OF NPCF'S MOST RECENT CLINICAL TRIALS8. EVALUATION OF DIGOXIN FOR RELAPSED NON-WNT, NON-SHH MEDULLOBLASTOMA (PHASE 2 STUDY) - THIS TRIAL WILL EVALUATE THE EFFICACY OF DIGOXIN IN TREATING PATIENTS WITH RELAPSED NON-SHH, NON-WNT MEDULLOBLASTOMA AND TO DETERIMINE IF DIGOXIN IMPROVES PROGRESSION FREE SURVIVIAL AT 4 MONTHS AFTER INITATION OF STUDY TREATMENT IN THIS PATIENT POPULATION. 9. METASTATIC EWING'S TRIAL TESTING SCHEDULE ENHANCEMENT TO IMPROVE OUTCOMES - THIS TRIAL WILL TEST OUR ABILITY TO ADMINISTER FREQUENTLY CHANGING CHEMOTHERAPY REGIMENS, CALLED SEQUENTIAL SECOND STRIKES, TO PATIENTS WITH WIDELY METASTATIC EWING SARCOMA TO STOP ITS DEVELOPMENT OF RESISTANCE TO CHEMOTHERAPY AND IMPROVE CURE RATES.SUNSHINE PROJECT LABORATORY THE SUNSHINE LAB CONTINUES WITH THE IMPORTANT TASK OF FINDING PROMISINGNEW TREATMENT REGIMENS FOR SARCOMAS, AMONG THE MOST DEADLY PEDIATRIC CANCER. DURING THIS PAST YEAR, THE SUNSHINE LAB HAS BUILT ON COMBINATION DRUG SCREENING PLATFORM AND FOCUSED ON OSTEOSARCOMA AND EWING SARCOMA.PEDIATRIC SARCOMAS OFTEN SHRINK OR GO AWAY WITH INITIAL THERAPY BUT THEN LATER RELAPSE AND ARE THEN MUCH MORE DIFFICULT TO CURE. THIS SUGGESTS THAT A SMALL AMOUNT OF DISEASE ELUDES CURRENT THERAPY. WE CONSIDER THIS SMALL, RESISTANT POPULATION SHOULD BE THE FOCUS OF PRECLINICAL RESEARCH AND HAVE 3 MAJOR PROJECTS RESULTING FROM THAT UNDERSTANDING OF PEDIATRIC SARCOMA. 1. WE HAVE DEVELOPED A MODEL OF THESE TWO COMPETING POPULATIONS,TERMED HETEROGENEITY, TO FIGURE OUT THE BEST STRATEGY TO ELIMINATE BOTH CANCER CELL POPULATIONS WITH TIMING AND COMBINATIONS OF THERAPIES. 2. IN COLLABORATION, WE ARE INVESTIGATING "SECOND STRIKES" IN BOTH OSTEOSARCOMA AND EWING SARCOMA. SECOND STRIKES ARE THERAPIES AFTER THE DISEASE HAS SHRUNK WITH INITIAL THERAPY. RATHER THAN SHRINK THE TUMOR,WE ARE INVESTIGATING THERAPIES TO ELIMINATE THE RESIDUAL CELLS BETTER THAN CONTINUING THE INITIAL THERAPY (FIRST STRIKE). THIS RESULTED FROM THE SUNSHINE LAB PARTICIPATING IN THE 9TH ANNUAL INTEGRATED MATHEMATICAL ONCOLOGY WORKSHOP AT MOFFITT CANCER CENTER. 3. IN COLLABORATION, WE HAVE FOCUSED ON A NEW, NON-MUTATED TARGET IN OSTEOSARCOMA, THE CMG HELICASE. WE HAVE BOTH IDENTIFIED THIS AS A WEAKNESS IN CANCER CELLS MORE THAN NORMAL CELLS AND IDENTIFIED A DRUG CLASS THAT HOLDS PROMISE AS AN EVENTUAL THERAPY. WE ARE EXPLORING THIS AGENT ALONE AND IN COMBINATION TO MAXIMIZE THE CHANCE FOR A SUCCESSFUL CLINICAL TRIAL. 4. IN COLLABORATION, WE ARE BUILDING ON PRIOR PUBLICATIONS SHOW ACTIVITY OF EPIGENETIC DRUGS LIKE PANOBINOSTAT AND EXPLORING MECHANISMS TO ENHANCE THIS THERAPY IN OSTEOSARCOMA. 5. IN COLLABORATION, WE ARE INVESTIGATING AN UNDERAPPRECIATED DNA REPAIR ENZYME AS AN ACHILLES HEEL IN EWING SARCOMA CALLED PARP16.

  Expenses $4,494,421 · Grants $2,820,170

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• ALBERT EINSTEIN COLLEGE OF MEDICINE

  $820,000

  FOR 43 CHALLENGE PROJECT - ENGINEERED DESTABILIZED AU RICH ELEMENTS OF C-MYC 3UTR AS THERAPEUTICS FOR C-MYC DRIVEN PEDIATRIC CANCERS AND ONE CARON META IN EWING SARCOMA TRIAL

• H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE

  $603,918

  IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT.

• THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  $400,000

  FOR 43 CHALLENGE PROJECT - TREATING LEPTOMENINGEAL SPREAD OF PEDIATRIC MEDULLOBLASTOMA WITH QUANTUM RADIOBIOLOGY

• PARATOPE BIO INC

  $300,000

  FOR 43 CHALLENGE PROJECT - HARNESSING THE POWER OF INNATE ANTIBODIES FOR NOVEL THERAPIES IN PEDIATRIC CANCER RESEARCH

• THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL

  $160,154

  IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT.

• CHILDREN'S HOSPITAL OF COLORADO FOUNDATION

  $126,526

  BIOMARKER TRIAL PILLAR PROJECT CONDUCTED UNDER THE SUNSHINE PROJECT

• H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION INC

  $100,104

  IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT.

• THE UNIVERSITY OF NORTH CARLINA AT CHAPEL HILL

  $56,763

  IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT.

• CONNECTICUT CHILDREN'S MEDICAL CENTER

  $52,971

  IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT.

• CHILDREN'S RESEARCH INSTITUTE

  $52,889

  IN SUPORT OF INKT TRIAL CONDUCTED UNDER THE SUNSHINE PROJECT

The 10 largest by cash amount. The API serves every itemized grant.

Provenance

Return type

form_990

Tax year

2023

Filed

22 October 2024

IRS schema version

2023v5.1

Source object

202432969349301628

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.